Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Vir Biotechnology (NASDAQ: VIR) has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's CEO, Marianne De Backer, M.Sc., Ph.D., MBA, is scheduled to take part in a fireside chat on Thursday, September 5, at 1:50 p.m. PT / 4:50 p.m. ET in New York City.
Investors and interested parties can access a live webcast of the fireside chat through the Events & Presentations section of Vir Biotechnology's website at www.vir.bio. The webcast will remain archived on the site for 30 days following the event, allowing those unable to attend the live session to catch up on the discussion.
Vir Biotechnology (NASDAQ: VIR) ha annunciato la sua partecipazione alla 22ª Conferenza Annuale Globale sulla Salute di Morgan Stanley. Il CEO dell'azienda, Marianne De Backer, M.Sc., Ph.D., MBA, è programmato per partecipare a una chiacchierata informale giovedì 5 settembre, alle 13:50 PT / 16:50 ET a New York City.
Investitori e interessati possono accedere a un webcast in diretta della chiacchierata attraverso la sezione Eventi & Presentazioni del sito web di Vir Biotechnology a www.vir.bio. Il webcast rimarrà archiviato sul sito per 30 giorni dopo l'evento, consentendo a coloro che non possono partecipare alla sessione dal vivo di recuperare la discussione.
Vir Biotechnology (NASDAQ: VIR) ha anunciado su participación en la 22ª Conferencia Anual Global de Atención Médica de Morgan Stanley. La CEO de la compañía, Marianne De Backer, M.Sc., Ph.D., MBA, está programada para participar en una charla informal el jueves 5 de septiembre, a las 1:50 p.m. PT / 4:50 p.m. ET en la ciudad de Nueva York.
Los inversores y partes interesadas pueden acceder a un webcast en vivo de la charla a través de la sección de Eventos y Presentaciones en el sitio web de Vir Biotechnology en www.vir.bio. El webcast permanecerá archivado en el sitio durante 30 días después del evento, permitiendo a quienes no puedan asistir a la sesión en vivo ponerse al día con la discusión.
Vir Biotechnology (NASDAQ: VIR)는 모건 스탠리 제22회 연례 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 CEO인 마리안 드 백커, M.Sc., Ph.D., MBA는 9월 5일 목요일에 오후 1:50 PT / 오후 4:50 ET에 뉴욕에서 진행되는 대화에 참석할 예정입니다.
투자자와 관심 있는 분들은 Vir Biotechnology 웹사이트의 이벤트 및 프레젠테이션 섹션을 통해 실시간 웹캐스트에 접속할 수 있습니다. 이 웹캐스트는 이벤트 후 30일 간 아카이브되어, 라이브 세션에 참석할 수 없는 분들이 토론 내용을 따라잡을 수 있습니다.
Vir Biotechnology (NASDAQ: VIR) a annoncé sa participation à la 22e Conférence Annuelle Mondiale sur la Santé de Morgan Stanley. Le PDG de l'entreprise, Marianne De Backer, M.Sc., Ph.D., MBA, est prévu pour participer à une discussion informelle le jeudi 5 septembre, à 13h50 PT / 16h50 ET à New York.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la discussion via la section Événements & Présentations du site web de Vir Biotechnology à www.vir.bio. Le webinaire restera archivé sur le site pendant 30 jours après l'événement, permettant à ceux qui ne peuvent pas assister à la session en direct de rattraper la discussion.
Vir Biotechnology (NASDAQ: VIR) hat seine Teilnahme an der 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley bekannt gegeben. Die CEO des Unternehmens, Marianne De Backer, M.Sc., Ph.D., MBA, wird am Donnerstag, den 5. September, um 13:50 Uhr PT / 16:50 Uhr ET in New York City an einem Gespräch teilnehmen.
Investoren und Interessierte können über den Abschnitt Veranstaltungen & Präsentationen auf der Website von Vir Biotechnology auf einen Live-Webcast des Gesprächs zugreifen unter www.vir.bio. Der Webcast bleibt für 30 Tage nach der Veranstaltung archiviert, sodass diejenigen, die nicht an der Live-Sitzung teilnehmen können, die Diskussion nachholen können.
- None.
- None.
A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Vir’s clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections, in addition to multiple oncology programs. Vir also has a preclinical portfolio of programs across a range of other infectious diseases and oncologic malignancies. Vir routinely posts information that may be important to investors on its website.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240822961651/en/
Media
Arran Attridge
Senior Vice President, Corporate Communications
aattridge@vir.bio
Investors
Richard Lepke
Senior Director, Investor Relations
rlepke@vir.bio
Source: Vir Biotechnology, Inc.
FAQ
When is Vir Biotechnology (VIR) participating in the Morgan Stanley Healthcare Conference?
Who will represent Vir Biotechnology (VIR) at the Morgan Stanley Healthcare Conference?
How can investors access Vir Biotechnology's (VIR) fireside chat at the Morgan Stanley conference?
How long will the webcast of Vir Biotechnology's (VIR) fireside chat be available?
